Agents targeting the vascular endothelial growth factor (VEGF) or the mechanistic target of rapamycin (mTOR) [3] are less effective against nccRCC compared with the more common clear-cell RCC (ccRCC) histology [4]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.